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ChemoembolizationAbstract Purpose: To study the ability of multidetector CT (MDCT) to diagnose arterioportal
shunts (APS) associated with hepatocellular carcinoma (HCC) and its impact on further manage-
ment of the patient.
Patients and methods: 252 Patients with HCC were examined by triphasic MDCT scanning. Images
were analyzed for the presence, locations, types and degrees of APS, being with or without throm-
bosis. Digital subtraction angiographies (DSA) were performed for 22 patients as a part of further
therapeutic management.
Results: MDCT revealed APS in 37 patients including 20 central, 9 peripheral and 8 mixed.
According to the degree we had 13 severe, 15 moderate and 9 mild APS. 18 patients had associated
portal venous thrombosis. During DSA examinations; APS were demonstrated in 19 out of 22 as 3
mild and peripheral shunts were faint and missed. Embolization of the shunt was performed in 17
patients prior to injection of the cytotoxic drug-lipiodol mixture. In one patient the APS was closed
to improve the hepatic status without further chemotherapy and in one patient the shunt was
ignored and not closed.
26 A.M. Mohamed et al.Conclusion: Good understanding of MDCT ﬁndings of APS complicating HCC contributes to the
diagnosis and improves the therapeutic outcome of the chemoembolization procedures.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Arterioportal shunt (APS) is an organic or functional commu-
nication between the high-pressure hepatic arterial branch and
low-pressure portal veins (1). Hepatocellular carcinoma
(HCC) can easily invade the adjacent portal vein to form the
direct communication between the hepatic artery or its
branches and portal veins, resulting in arterioportal shunt
(APS). Hepatic APS may cause or aggravate portal hyperten-
sion and consequently, splenomegaly, bleeding from esopha-
geal varices and hepatic encephalopathy, accelerating intra
hepatic dissemination and extra hepatic metastasis of tumor
cells (2).
One of the most important lines of palliative treatment of
HCC is trans-catheter chemo-embolization (3). The formation
of HCC-associated APS may bring some difﬁculty and danger
to the procedure, such as cause chemotherapy drug and em-
bolic agent to run-off through shunt path, and result in aber-
rant embolism (4). The embolic agent will be diverted to
branches of the portal vein and delivered to normal areas of
the liver instead of being deposited in the tumor, a problem
which can be overcome by super selective embolization of
the APS using micro catheters if the condition is diagnosed be-
fore treatment (5).
Transcatheter hepatic angiography, including digital sub-
traction angiography (DSA) is the gold standard for diagno-
sis of HCC-associated APS, but has the disadvantage of
being an invasive procedure (2). Multidetector CT (MDCT)
could contribute to the diagnosis of hepatic APS complicat-
ing HCC due to its fast scanning and improved image reso-
lution and quality (6). CT hepatic arteriography ﬁndings in
APS have a major impact on planning the way in which
chemoembolization treatment could be performed. Findings
of this modality may alter treatment plans for the tumor
and the shunts involving selective administration of chemo
embolic material (7), so understanding of CT diagnostic cri-
teria of hepatic APS complicating HCC is of signiﬁcant clin-
ical implications.
The aim of this study was to investigate the ability of mul-
tidetector CT (MDCT) to diagnose arterioportal shunt (APS)
complicating hepatocellular carcinoma (HCC) and the impact
of that on further patient’s management.2. Patients and methods
This prospective study was carried out in the Radiodiagnosis
Department of Ain Shams University Hospital and in some
private centers between February 2011 and January 2013.
Multidetector CT was conducted for 252 patients with HCC.
They included 214 males and 38 females and their ages ranged
between 39 and 75 years. An informed consent was obtained
from each patient before the study. The diagnosis of HCC
was based on the classical ﬁndings of enhancing lesions at
the arterial phase with rapid wash out of the contrast at thevenous phase, associated with elevated/progressively rising al-
pha fetoprotein level. Some cases were conﬁrmed by percuta-
neous needle biopsy.
Helical CT scans were performed using at least 8 slice
multi-detector scanners (GE Healthcare, Milwaukee, WI,
USA) with a kV of 140, 200–300 mA and 0.8-s gantry
rotation time. Most patients were examined after an over-
night or 6 h fast, with water (or sometimes gastrograﬁn)
being used to mark the stomach and bowel loops. Dy-
namic CT scans were acquired after the injection of 80–
120 cc iodinated contrast medium (Ultravist 300; Schering,
Berlin, Germany or Iopamiro 300; Bracco, Milano, Italy)
at a pressure of 600 PSI and a rate 4 ml/s using an auto-
matic pump injector (Angiomat 6000; Liebel-Flarsheim)
and via an 18- or 20-gauge canula inserted into an ante-
cubital or peripheral upper limb vein. The scans were ac-
quired in the early arterial, late arterial and porto-venous
phases after a delay of 15, 25 and 60 s respectively.
The patients were not instructed to maintain strict
apnea. Instead; they were imaged during gentle shallow
breathing.
We used an effective slice thickness of 7 mm and the
images were reconstructed at 10 mm intervals to achieve an
overlap of 40–50%. The images were then further recon-
structed at 1 mm thickness/intervals producing about 150–
200 sections per acquisition and sent to workstation (Hp
xw 8600, AW Volume share 4, GE medical systems SCS,
France) where coronal and sagittal reformats were acquired.
Volume rendering techniques were also used particularly the
maximum intensity projection (MIP) to demonstrate the
small peripheral vessels.
The CT diagnostic criteria for APS were earlier enhance-
ment or stronger opaciﬁcation of main portal trunk and/or
its ﬁrst-order branches than that of superior mesenteric or
the splenic vein; or earlier enhancement or stronger opaciﬁca-
tion of the second-order and smaller branches of portal veins
than that of the main portal trunk (8).
Depending upon the location of shunt, APS were classi-
ﬁed into three types: The central type was the shunt located
at the porta hepatis with earlier enhancement and/or stron-
ger opaciﬁcation of the main portal trunk and/or the ﬁrst-
order branches at the hepatic arterial phase. The peripheral
type was the shunt located in the peripheral liver paren-
chyma with earlier enhancement and/or stronger opaciﬁca-
tion of the second order and smaller branches of the
portal vein, or transient patchy or wedge-shaped enhance-
ment peripheral to HCC foci at the late hepatic arterial
phase. The mixed type showed both central and peripheral
criteria (2).
According to the time of appearance of APS on images,
APS were divided into three degrees. The severe APS showed
opaciﬁcation of the main portal trunk and/or the ﬁrst-order
branches with enhancement of the hepatic artery and its
branches at the early hepatic arterial phase, with no or mild
enhancement of HCC foci. The moderate APS demonstrated
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branches with middle or late enhancement of HCC foci at
the late hepatic arterial phase. The mild APS revealed
opaciﬁcation of the second-order and smaller branches of
the portal veins at the late hepatic arterial phase, with
transient patchy or wedge-shaped enhancement peripheral
to HCC foci (2).
The interventional procedures were carried out at the inter-
ventional radiology units of Ain Shams University hospitals. A
femoral arterial approach was used with the Seldinger tech-
nique. The hepatic artery was catheterized with a 5F polyeth-
ylene catheter with cobra head conﬁguration (C2 Cordis

USA) in 17 cases and a reverse 5F catheter (Simmonds S2,
Cordis

USA) in ﬁve cases. The catheter was advanced into
the proximal hepatic artery and an initial subtracted angio-
gram was obtained after hand injection of 8 cc of non ionic
contrast (Ultravist 300; Schering, Berlin, Germany) to detect
the arterioportal ﬁstula. The catheter was further advanced
so that the feeding artery of the ﬁstula was super selectively
catheterized and embolization was done under ﬂuoroscopic
guidance with serial repeated control angiograms. Evidence
of successful embolization was deﬁned by complete stasis of
the injected contrast and embolizing material. In some casesFig. 1 Central severe ﬁstula: 56 year old male patient with liver cirrh
and B) Axial sequential CT cuts show marked enhancement of the rig
hepatoma (arrow in B). (C) DSA of the right hepatic artery conﬁrms th
portal vein (arrow). (D) Super selective hepatic arteriogram after embo
with no ﬁlling of the right portal vein.we used a 3.8 f micro catheter (Renegade, Boston Scientiﬁc 
USA).
In cases of mild, moderate or peripheral shunts we used gel
foam as the embolizing material, being cut into small pledges
and mixed with contrast. In cases of central and severe shunts
we used N-butyl-2-cyanoacrylate (Histoacryl) mixed with
lipiodol with a 1:1 ratio.
3. Results
MDCT scanning revealed 37 APS in 252 patients with HCC.
They were classiﬁed according to their location as 20 central,
9 peripheral and 8 mixed, and according to their degree as
13 severe, 15 moderate and 9 mild.
The study included 6 central and severe APS (Fig. 1), 11
central and moderate APS (Fig. 2), 9 peripheral and mild
APS (Figs. 3 and 4), 2 mixed and severe APS (Fig. 5) and 7
mixed and moderate APS (Fig. 6). Wedge-shaped enhance-
ment peripheral to HCC foci was noted in 3 patients with mild
and peripheral APS (Fig. 7).
MDCT showed that 18 patients with APS also had portal
venous thromboses including 4 patients with partial tumoral
thrombosis in the main portal vein and total thrombosis inosis and large posterior right hepatic lobe HCC at segment VI. (A
ht portal vein during the early arterial phase (arrow in A) and the
e presence of the ﬁstula with ﬁlling of posterior branch of the right
lization of the ﬁstula using N-butyl-2-cyanoacrylate (Histoacryl)
Fig. 2 Moderate central APS: 67 year old male patient with liver cirrhosis and nodular HCC at the vicinity of the right main portal vein.
(A) Axial CT cut at the late arterial phase shows enhancement of the HCC (arrow). (B) More caudal scan shows shunting of the contrast
to the right portal vein. (C) Thrombosis of the right portal vein is conﬁrmed at the portal venous phase (arrow). No intervention could be
performed and Sorafenib was recommended for further management.
28 A.M. Mohamed et al.right portal veins, two of them with sectorial differential hyp-
odensity of the right hepatic lobe suggesting infarction (Fig. 8).
Six patients had thromboses in the right portal vein (Fig. 6), 5
patients had thrombosis in the proximal part of the left portal
vein (Fig. 5), and lastly 3 patients with thrombosis in the distal
part of the left portal vein. Accordingly; we had 19 APS pa-
tients without portal vein thrombosis.
In most patients with central severe or moderate shunts, the
degree of enhancement of the hepatic and splenic parenchyma
was relatively decreased.
Depending upon the data obtained from MDCT, DSA
was performed for 22 patients who were suitable for
chemoembolization, taking into consideration the guidelines
of the American Association for the Study of Liver Dis-
eases (AASLD) and Barcelona Clinic of Liver Cancer
(BCLC) staging systems (9), and each case was discussed
and evaluated individually by a multi-disciplinary tumor
board.
DSA showed nineteen out of the twenty-two APS while
3 mild and peripheral APS were faint and missed by
DSA.
These 19 APS were managed as follows: Embolization of
the shunt was performed in 17 cases prior to injection of
cytotoxic drug-lipiodol mixture, one APS was closed only
without chemotherapy and the other one was ignored and
not closed.4. Discussion
Hepatocellular carcinoma is a leading cause of morbidity and
mortality worldwide, accounting for approximately 1 million
deaths per year, fueled by the increasing incidence of viral hep-
atitis (7).
The major etiological factor of liver cancer is hepatitis B
virus (HBV), followed by hepatitis C virus (HCV) infection.
In Egypt, HBV and HCV are considered major health prob-
lems and disease prognosis may be worse in conjunction with
schistosomiasis. Accordingly, the incidence of HCC in Egypt is
among the highest in the world (10).
Arterioportal shunts are the most common vascular com-
munications associated with advanced HCC (11).
In HCC patients treated with transarterial chemoemboliza-
tion, hepatic AP shunts may be problematic because chemo-
therapeutic agents go through the shunts and may cause
systemic toxicity as well as decrease the chemotherapeutic ef-
fects against the tumor (12).
Trans-catheter hepatic angiography has been the gold stan-
dard for diagnosis of APS in the past and can reveal the shunt
locations, types and degrees. However, it is an invasive exam-
ination and may fail due to anatomic variations of the hepatic
artery. Also mild and peripheral APS may be missed because
of unsatisfactory opaciﬁcation of the hepatic artery or faint
shunt especially when associated with massive HCC (2).
Fig. 3 Peripheral mild ﬁstula: 47 year old male patient with liver cirrhosis and right hepatic lobe HCC. (A) MIP hepatic arteriogram
showing small arterio-portal ﬁstula near the dome of the right lobe (arrow). (B) Coronal reformat at the porto-venous phase clearly
demarcates the HCC due to rapid wash out of the contrast (arrow). (C) DSA of the right hepatic artery conﬁrms the presence of the ﬁstula
and shunting of contrast to the small peripheral portal vein. (D) Selective catheterization and embolization of the ﬁstula using gel foam
particles followed with injection of cytotoxic drug/lipiodol mixture (E). Post chemoembolization of CT scan. The lipiodol is well
concentrated within the lesion.
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and greatly reduces the time of volume scanning. It offers thin-
slice and dynamic enhancement scanning of the liver at early
and late arterial phases, and portal venous phase demonstrat-
ing clearly the blood supply of the liver and the hemodynamic
changes of APS, providing a fast, effective and noninvasive
diagnostic method for examination of APS complicating
HCC (2).
Clinically, correct interpretation of MDCT ﬁndings
of HCC associated APS could assist in making right
diagnosis and working out effective therapeutic strategy
(13).In our study, MDCT detected 37 APS in 252 HCC pa-
tients (14.7%) in near accordance to the ﬁndings of Luo
et al. (2) as they found 56 APS in 282 HCC patients
(19.8%) and the results of Vogl et al. (14) as 7 out of 39
HCC patients (17.9%) had associated APS. MDCT displayed
all types and degrees of the thirty-seven APS. Three out of
nine (33%) peripheral and mild APS were faint and missed
by DSA, very near to the ﬁndings of Luo et al. (2) as two
out of seven (29%) mild and peripheral APS were missed
by DSA.
Depending on data obtained from MDCT, digital subtrac-
tion angiograms were performed only for 22 APS patients (out
Fig. 4 Peripheral mild APS: 49 year old female patient with liver cirrhosis and HCC at the lateral segment of the left lobe. (A) Axial MIP
at the arterial phase shows shunting of the contrast to the 2nd order branches of the left portal vein (arrow). (B) DSA shows tumor blush
(red arrow) and conﬁrms the presence of the APS, with ﬁlling of the left portal branch (white arrow). (C) The ﬁstula was embolized using
gel foam and cytotoxic lipiodol mixture was injected. (D) The artery involved in the shunt is embolized (white arrow) and the HCC is
successfully outlined with lipiodol (red arrow).
30 A.M. Mohamed et al.of 37) who were candidates for chemoembolization or those
suitable for closure of APS by arterial embolization. They in-
cluded 19 patients without portal venous thrombosis and 3 pa-
tients with thrombosis of the distal (peripheral) part of left
portal vein.
Seventeen APS were embolized ﬁrst and then the HCC
masses were treated by cytotoxic drug-lipiodol mixture to
ensure adequate concentration of the mixture in the tu-
mor. APS was closed only without chemotherapy in one
patient just to alleviate the patient’s symptoms resulting
from complications of the APS. One APS was not closed
being mild, peripheral and away from the main bulk of
the HCC mass being supplied by another non shunting
artery. This HCC mass was treated by cytotoxic drug-lipi-
odol mixture therapy and then embolizing its feeding ar-
tery. Three mild and peripheral APS were missed by
DSA.
Fifteen out of thirty-seven patients with APS had
thrombosis of the main portal trunk, main right or main left
portal veins. These patients were given only liver support as
they were not suitable for chemoembolization or closure ofthe shunts according to the opinion that transarterial
chemoembolization has limited value as palliative treatment
of cases associated with major portal vein invasion due to
the possibility of liver failure following embolization and that
it may predispose to hepatic infarction (14). Our multi-disci-
plinary tumor board coincided also with this opinion regard-
ing these patients.
Materials used for embolization include coils, glue, alco-
hol, and detachable balloons. For many years, coils were con-
sidered the best devices for this indication (15). However, we
used gel foam as the main embolizing agent in our cases, due
to its availability, low cost and the ability to cut into variable
sizes according to the diameter of the target vessel, as the
main goal was to ensure good concentration of cytotoxic
drug/lipiodol mixture in the tumor and prevent systemic tox-
icity. The combination of coils and N-butyl-2-cyanoacrylate
in cases of large ﬁstula has been done by some authors
(16,17). In our study we used Hystoacryl in two cases with
large ﬁstulas because of its good penetration, dispersion that
is freer than that for other embolizing materials, and rapid
induction of thrombosis and permanent occlusion after
Fig. 5 Mixed severe APS: 75 year old male patient with liver cirrhosis and nodular HCC at segment IV of the relatively hypertrophied
left lobe. (A) Axial CT cut at the arterial phase shows enhancement of the left portal veins as far as the 2nd order branches, with ill deﬁned
intra-luminal ﬁlling defect at the left main portal vein (red arrow). (B) Partial thrombosis of the left portal vein is conﬁrmed at the portal
venous phase (arrow head). (C) The HCC is better seen at the venous phase due to wash out of the contrast (arrow).
Fig. 6 Mixed moderate APS: 55 year old male patient with liver cirrhosis and nodular HCC at segment IV of the left lobe. (A) Axial
MIP image at the late arterial phase shows enhancement of the right main portal vein (red arrow) as well as the 2nd order branches of the
left portal vein (black arrow), with non obstructing thrombus at the right portal vein (white arrow) (B) The HCC is seen at the porto-
venous phase with central necrotic core (arrow). Medical liver support was considered for the patient.
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or saline. Although non-target embolization can occur, we
found it safe and effective for treating ﬁstulas as we embol-ized only abnormal vessels. No signiﬁcant complications
related to embolization were encountered during the course
of the study.
Fig. 7 Mild peripheral APS: 50 year old male patient with wedge-shaped enhancement peripheral to HCC (arrows). The patient was
referred for selective chemoembolization.
Fig. 8 Central APS with portal venous thrombosis: 57 year old male patient with liver cirrhosis and diffuse neoplastic inﬁltration of the
right lobe. (A) Axial CT at the arterial phase shows intense enhancement of the right and left portal veins (red arrows) with differential
enhancement of the right and left lobes (B) Non-obstructing mural thrombus is present at the main portal vein (arrow) (C) The right portal
vein shows tumoral thrombosis (arrow). The hypodensity of the right lobe reﬂects an element of infarction. No interventional procedure
was done and further management was carried out by medical liver support.
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Triphasic thin-slice MDCT is an effective and noninvasive
technique that could diagnose the different types and degrees
of HCC-associated APS in our study. Good understanding
of MDCT ﬁndings of these shunts warranted closure of the
shunt during the chemoembolization procedure in many pa-
tients to improve the therapeutic outcome and avoid escape
of the embolic agent to non-tumoral parts of the liver.6. Conﬂict of interest
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